Table 3.
Adverse pathological outcomes | Adjusted ORa | 95% CI | P value |
---|---|---|---|
High‐grade disease | P < 0.0001 | ||
Light vs normal | 1.78 | 1.22‐2.60 | 0.003 |
Moderate/severe vs normal | 5.50 | 2.53‐11.99 | <0.0001 |
High pT stage (≥pT3) | P < 0.0001 | ||
Light vs normal | 1.81 | 1.28‐2.54 | 0.001 |
Moderate/severe vs normal | 3.64 | 2.16‐6.13 | <0.0001 |
Lymph node involvement | P = 0.587 | ||
Light vs normal | 1.31 | 0.74‐2.34 | 0.357 |
Moderate/severe vs normal | 1.39 | 0.62‐3.08 | 0.422 |
LVI | P = 0.004 | ||
Light vs normal | 2.09 | 1.26‐3.47 | 0.004 |
Moderate/severe vs normal | 2.61 | 1.35‐5.04 | 0.004 |
Sessile carcinoma | P < 0.0001 | ||
Light vs normal | 1.86 | 1.30‐2.68 | 0.001 |
Moderate/severe vs normal | 2.56 | 1.43‐4.59 | 0.002 |
CVH | P = 0.007 | ||
Light vs normal | 1.35 | 0.89‐2.05 | 0.160 |
Moderate/severe vs normal | 2.41 | 1.40‐4.16 | 0.002 |
PSM | 0.025 | ||
Light vs normal | 1.36 | 0.7‐2.66 | 0.361 |
Moderate/severe vs normal | 2.98 | 1.34‐6.59 | 0.007 |
CI, confidence interval; CVH, concomitant variant histology; LVI, lymphovascular invasion; OR, odds ratios; PSM, positive surgical margins.
Adjusting for age, gender, body mass index, hydronephrosis, tumor side, tumor location and multifocality.